

February 13, 2002

**Urgent: Priscoline® Ampuls
Scheduled for Discontinuation in 2nd Quarter 2002
Second Notification**

Dear Healthcare Provider:

You may recall that I wrote to you in May of 2001 about our plans to discontinue distribution of Priscoline® hydrochloride ampuls (tolazoline hydrochloride injection), sometime this year. I am writing now to confirm that we expect to deplete our very limited remaining supplies of Priscoline® during the second quarter of 2002.

Priscoline® is indicated for the treatment of persistent pulmonary hypertension of the newborn. In recent years, the use of Priscoline® in pulmonary hypertension in neonates has been replaced by newer therapies.

Current options for the management of persistent pulmonary hypertension of the newborn include: correction of alveolar hypoxia/hypercarbia; prostaglandins; vasodilators; extracorporeal membrane oxygenation; and nitric oxide. If you or your colleagues have medical questions regarding Priscoline®, please telephone the Novartis Customer Interaction Center at 877 787-8246.

We appreciate your understanding and support during this period.

Sincerely,

Stephen Cunningham, MD
Vice President, Medical Affairs
Medical Affairs Department
Novartis Pharmaceuticals Corporation